Liraglutide Cost in District of Columbia 2026

What Does Liraglutide Actually Cost in DC in 2026?

The cash price for liraglutide in the District of Columbia ranges from roughly $900 per month at retail pharmacies to $1,349 per month at list price. Your actual out-of-pocket cost depends on which brand you are prescribed, which pharmacy you use, whether you carry commercial insurance, and whether you qualify for manufacturer or patient-assistance programs.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA under two brand names: Victoza (1.2 mg or 1.8 mg daily for type 2 diabetes) and Saxenda (up to 3.0 mg daily for chronic weight management). The FDA approval documents for both products are posted on the agency's drug database. Both formulations use the same molecule; the difference is dosing range and labeled indication.

In the SCALE Obesity and Prediabetes trial (N=3,731), 56-week treatment with liraglutide 3.0 mg produced a mean body-weight reduction of 8.0% compared with 2.6% for placebo (P<0.001). [1] That efficacy signal drove broad commercial adoption and, with it, high list prices. Without insurance or a savings program, most DC residents filling a Saxenda prescription will pay close to the $900 average cash price, not the manufacturer list.

Victoza's cash price at DC pharmacies tends to run slightly lower than Saxenda's because the diabetes indication has a longer generic-entry timeline under consideration, but no true small-molecule generic for liraglutide exists as of 2026. Biosimilar development is underway in the broader GLP-1 category, though no FDA-approved liraglutide biosimilar has launched in the United States yet. The FDA's biosimilar product information page tracks approval status as it changes.

GoodRx and similar discount platforms can bring the retail cash price for a 3 mL Saxenda pen (18 mg/3 mL) to roughly $850 to $950 at major DC-area pharmacies including CVS, Walgreens, and Giant. Using a coupon code at the pharmacy counter does not count toward your insurance deductible, which matters if you are trying to satisfy a high-deductible plan.

DC Medicaid Coverage for Liraglutide

DC Medicaid covers liraglutide for both type 2 diabetes (Victoza) and chronic weight management (Saxenda), but prior authorization is required for both indications. Coverage is not automatic.

DC's Medicaid program, administered through DC Healthy Families, aligns its preferred drug list (PDL) with evidence-based prescribing standards. For the diabetes indication, prescribers must typically document that a beneficiary has a confirmed type 2 diabetes diagnosis, an A1C above a threshold specified in the PA form (commonly 7.5% or higher), and inadequate response to first-line agents such as metformin. For Saxenda under the weight-management indication, PA criteria generally require documentation of a body mass index (BMI) of 30 kg/m² or higher, or BMI of 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes who need additional glycemic control with weight loss benefit, GLP-1 receptor agonists with demonstrated cardiovascular benefit are recommended." [2] That language strengthens PA arguments for liraglutide specifically when a DC Medicaid patient also carries cardiovascular risk.

Approval timelines for DC Medicaid PA requests vary. Standard PA decisions are generally due within 3 business days under federal Medicaid managed care regulations at 42 CFR 438.210. Expedited requests, where a standard timeline could seriously jeopardize the enrollee's health, must be resolved within 24 hours. If the PA is denied, DC residents have the right to appeal through the DC Office of Administrative Hearings.

Prescribers submitting a PA should include: the patient's current weight and BMI calculation, relevant lab results (A1C for diabetes, fasting glucose, lipid panel where applicable), documentation of prior weight-loss or diabetes therapy and outcomes, and any relevant comorbidity diagnoses with ICD-10 codes. A complete first submission reduces the chance of a technical denial and avoids re-authorization delays.

Commercial Insurance and Prior Authorization in DC

Most commercial plans sold through DC Health Link (the DC ACA marketplace) cover liraglutide, but nearly all require prior authorization and place it on a specialty or non-preferred tier. That tier placement directly affects the copay.

Tier 3 (preferred brand) placements typically generate copays of $50 to $150 per fill on standard formularies. Tier 4 or specialty tier placements can push copay amounts to 20% to 33% of the allowed cost, which on a $900 allowed price means $180 to $297 per month even with insurance. Checking your specific formulary tier before the prescription is written saves time and money.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity states that anti-obesity medications should be considered for patients with BMI of 30 kg/m² or higher, or BMI 27 kg/m² or higher with weight-related comorbidities, and that access barriers including cost and insurance coverage are a recognized obstacle to care. [3] That guideline language is useful documentation when appealing a commercial plan denial.

Employers with self-insured plans (common among DC's large federal contractor and nonprofit employer base) set their own formularies and may exclude weight-loss drugs even when they cover the same molecule for diabetes. Checking whether your employer plan is self-insured (ask your HR benefits coordinator) matters because ACA non-discrimination rules apply differently to self-insured plans.

For patients with Medicare Part D, Saxenda is generally not covered under current law for the weight-loss indication, because Medicare was historically prohibited from covering drugs for weight loss alone. The Treat and Reduce Obesity Act, if passed, would change that, but it had not been enacted as of the publication date of this article. Victoza for diabetes is covered under Part D formularies, subject to plan-specific tier placement and PA requirements.

Compounded Liraglutide in DC: What Is Legal?

Compounded liraglutide from a licensed 503A compounding pharmacy is legally available to DC residents when prescribed by a licensed practitioner, and prices typically run around $150 per month, a fraction of the brand-name cost.

503A pharmacies compound drugs for individual patients based on a valid prescription. They operate under state board of pharmacy oversight rather than full FDA manufacturing standards. DC's Board of Pharmacy regulates 503A facilities operating within the District, and DC residents may also receive compounded prescriptions from 503A pharmacies licensed in other states that ship to DC, provided those pharmacies comply with their home-state laws. The FDA's overview of compounding regulations explains the 503A versus 503B distinction.

The FDA does not approve compounded drugs for safety or efficacy. For liraglutide specifically, the FDA placed semaglutide (a related GLP-1 agonist) on its drug shortage list in prior years, which created a specific legal pathway for compounding. Liraglutide's shortage status has fluctuated. The FDA's current drug shortage database is the authoritative source for real-time status. When a drug is not on the shortage list, 503A pharmacies may still compound it for individual patients under the "essentially a copy" rules, but 503B outsourcing facilities face tighter restrictions.

Clinically, compounded liraglutide uses the same amino acid sequence as the branded product. Concentration, excipients, and sterility practices vary by pharmacy. Patients using compounded liraglutide should confirm that the dispensing pharmacy is in good standing with its state board and that the product has been tested for potency and sterility by a third-party laboratory. Asking the pharmacy for a certificate of analysis (COA) is a reasonable step before first use.

The HealthRX clinical team uses a four-question decision framework when advising DC patients on whether compounded liraglutide is appropriate: (1) Is the patient uninsured or underinsured with documented inability to afford brand-name liraglutide? (2) Has the prescribing clinician reviewed the compounding pharmacy's most recent COA and state license status? (3) Does the patient understand that the compounded product is not FDA-approved and that the prescriber will monitor for expected therapeutic response? (4) Is there a 90-day reassessment plan with weight, glycemic, or cardiovascular metrics defined in advance? A "yes" to all four supports proceeding; any "no" triggers a discussion before the prescription is sent.

Savings Programs and Patient Assistance in DC

Novo Nordisk offers savings cards for both Saxenda and Victoza that can reduce out-of-pocket costs for commercially insured patients, though these cards do not apply to government-funded programs like Medicaid or Medicare.

The Novo Nordisk Saxenda savings card has historically capped patient cost at $25 per 30-day supply for eligible patients, subject to program terms and income limits. Eligibility requires commercial insurance coverage. DC residents without insurance do not qualify for the savings card but may qualify for the Novo Nordisk Patient Assistance Program (PAP), which provides free medication to patients who meet income thresholds, generally at or below 400% of the federal poverty level. Applications go through NovoCare, Novo Nordisk's patient services program.

For patients who do not qualify for PAP and cannot afford the retail cash price, GoodRx and similar platforms reliably reduce the cost at DC pharmacies by 20% to 40% off the cash price. Stacking a GoodRx coupon with a pharmacy loyalty card is not always possible, so comparing the GoodRx price against the pharmacy's own discount program is worth doing before checkout.

Community health centers in DC operating under Federally Qualified Health Center (FQHC) status have access to 340B drug pricing, which can dramatically reduce the cost of liraglutide for eligible low-income patients. Mary's Center, Unity Health Care, and Community of Hope are among DC FQHCs that serve patients regardless of insurance status and may dispense 340B-priced medications through in-house or contracted pharmacies.

Telehealth Prescribing of Liraglutide in DC

Telehealth prescribing of liraglutide is legal in the District of Columbia, and DC telehealth law does not require an in-person visit before a prescription is issued for most chronic condition indications.

DC adopted permanent telehealth flexibilities that allow prescribers licensed in DC to conduct an initial evaluation, establish a patient-provider relationship, and issue a valid prescription for liraglutide entirely via audio-video visit. The DC Department of Health maintains current telehealth policy guidance for licensed practitioners. Prescribers using telehealth platforms must still comply with controlled substance prescribing rules (liraglutide is not a controlled substance, so DEA registration requirements do not apply), maintain a medical record documenting the clinical encounter, and obtain informed consent per standard DC medical practice requirements.

For weight management specifically, the SCALE Obesity trial published in the New England Journal of Medicine demonstrated that liraglutide 3.0 mg daily for 56 weeks reduced body weight by 8.0% versus 2.6% with placebo, and 63.2% of participants achieved at least 5% weight loss compared with 27.1% on placebo (P<0.001). [1] That trial enrolled adults with BMI of 30 kg/m² or higher, or BMI 27 kg/m² or higher with dyslipidemia or hypertension, which maps directly to the patient population a telehealth provider in DC would evaluate.

Telehealth platforms serving DC residents typically ship medication to a DC-licensed pharmacy or mail the prescription electronically. If the patient opts for a compounding pharmacy, the telehealth prescriber's electronic prescription must be directed to a pharmacy licensed to receive electronic prescriptions under DC pharmacy law.

How Liraglutide Compares to Other GLP-1 Options Available in DC

Liraglutide is one of several GLP-1 receptor agonists available to DC patients in 2026, and understanding the cost and efficacy differences helps contextualize whether it is the right choice for a given patient.

Semaglutide (Ozempic for diabetes, Wegovy for weight management) is the most widely discussed comparator. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. [4] That is a larger absolute weight reduction than the 8.0% seen with liraglutide in SCALE, though the trials differ in population, duration, and design, and direct head-to-head data are limited.

Semaglutide's list price (Wegovy) runs higher than liraglutide's Saxenda in 2026, but semaglutide's once-weekly dosing versus liraglutide's once-daily injection is a practical advantage for some patients. For type 2 diabetes management, dulaglutide (Trulicity) and exenatide (Bydureon BCise) are additional once-weekly options with different cardiovascular outcome trial profiles.

The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced major adverse cardiovascular events (MACE) by 13% relative to placebo in adults with type 2 diabetes and high cardiovascular risk (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority). [5] That cardiovascular benefit data is material to insurance PA arguments and to the clinical decision between GLP-1 agents for patients with established cardiovascular disease.

Tirzepatide (Mounjaro for diabetes, Zepbound for weight management), a dual GIP/GLP-1 agonist, has shown larger weight loss in trials than either liraglutide or semaglutide, but its cost in DC follows a similar high list-price pattern. For patients with DC Medicaid or limited commercial coverage, liraglutide's longer track record and more established PA pathways can make it the more accessible option in practice.

What DC Patients Should Do Before Their First Fill

Before sending a liraglutide prescription to a DC pharmacy, patients and prescribers should work through a practical checklist that addresses cost, coverage, and monitoring.

First, confirm the indication. Victoza (diabetes) and Saxenda (weight management) have different NDC numbers and different formulary placements on most DC insurance plans. Sending the wrong brand to the pharmacy delays the fill and may trigger a different PA requirement.

Second, check the formulary tier for your specific plan. DC Health Link plans vary significantly by insurer (Kaiser Permanente, CareFirst BlueCross BlueShield, and UnitedHealthcare are among the larger carriers in DC), and liraglutide's tier can differ between them even within the same metal level.

Third, if the cash price is the only option, compare GoodRx, RxSaver, and the pharmacy's own discount program before checkout. The difference between platforms at a single DC pharmacy can be $50 to $100 per fill.

Fourth, if cost remains prohibitive, discuss compounded liraglutide with your prescriber and ask specifically about the compounding pharmacy's COA process and state license status.

Fifth, schedule a follow-up visit at 12 weeks. The SCALE trial's responder analysis showed that patients who did not achieve at least 4% body-weight reduction by week 16 were unlikely to reach meaningful long-term weight loss on liraglutide. [1] Identifying non-responders early allows a timely switch to an alternative agent rather than continued spending on a drug that is not working for that individual.